AN2 Therapeutics, Inc. (ANTX) at Guggenheim 3rd Annual Healthcare Innovation Conference - AN2 THERAPEUTICS INC

Explicit Guidance:

• No explicit financial guidance (revenue, earnings, margins, capex, cash flow) provided for any future period, consistent with the pre-revenue clinical stage of the company.

Business-Segment Outlook:

• Polycythemia Vera (PV): Phase 2 trial to commence with a 10-patient sentinel cohort in December; 75 total patients planned across Part 1 (open-label) and Part 2 (randomized withdrawal). Sentinel data readout expected Q1 2027 (approx. May 2027 for initial robust data). Long-term extension data expected throughout 2027. Management targets oral hematocrit control comparable to or exceeding injectable benchmarks (e.g., Ruspertide).
• Chagas Disease: Phase 2 trial (60 patients, two-dose) initiated early 2027 in Bolivia (10% prevalence); enrollment expected to be rapid (20–30 patients/site/month). Data readout targeted for the second half of 2027. Drug expected to be PRV (Pediatric Reviewer's View) eligible under Orphan Drug Act.
• Non-Tuberculous Mycobacteria (NTM - MAC): Pivot to Mycobacterium abscessus (treatment-naive, early-stage patients) based on 250x higher potency vs. MAC. Aim to replace chronic IV-only regimens (e.g., imipenem/amikacin) with an oral regimen.
• Hypophosphatasia: Program announced recently; Phase 1 initiation expected in 2027.
• Oncology (PI3K): Pan-mutant PI3K inhibitor program currently in research/preclinical; aiming for a strategic partner with preclinical data in early 2027.

Market and Competitive Outlook:

• PV: Anticipates market shift toward oral therapies, differentiating from current injectable-only standards (e.g., Ruspertide). Sees opportunity to control hematocrit in poorly controlled patients (<50%).
• Chagas: Addresses a silent killer with no approved chronic adult treatments; U.S. prevalence estimated at 300,000+ (potentially underreported). High unmet need in Bolivia (10% population) and Latin America.
• NTM: Targets a high-risk patient population requiring months/years of IV chemotherapy; aims to disrupt the off-label IV-only standard with a curative oral option.
• Oncology: Positions pan-mutant PI3K inhibitor as "third-generation" technology (vs. Relay's 2nd-gen), targeting 50x kinase separation and improved wild-type/helicase separation to mitigate hyperglycemia, targeting partners with large breast cancer franchises.

Macro / Industry Outlook:

• Regulatory: FDA clearance obtained for PV Phase 2; Australia and India regulatory status also secured. Expectance of PRV eligibility for Chagas.
• Geography: Strategic focus on Bolivia for Chagas trial recruitment due to highest global disease prevalence; U.S. market size driven by blood supply screening estimates.

Strategic Initiatives:

• Platform Expansion: Utilizing boron chemistry platform to expand from infectious disease (Chagas, NTM) and hematologic (PV) into oncology (pan-mutant PI3K) and bone disease (hypophosphatasia).
• Partnership Strategy: Active search for strategic partners for the preclinical oncology program; preclinical validation models deemed sufficient to attract partner interest without clinical data.
• Pipeline Inflection Points: Key milestones scheduled throughout 2027, including Sentinel dosing (Dec), Part 1 enrollment, Chagas readout (H2 2027), and Hypophosphatasia Phase 1 start.

Risks and Headwinds to Outlook:

• Clinical Trial Execution: Enrollment speed dependent on site experience with PV trials; potential variability in dosing curves specific to PV patients compared to non-PV cohorts.
• Efficacy Translation: Unconfirmed if the red blood cell-specific effect observed in non-PV patients and NHP models will translate to the same degree in PV patients.
• Regulatory/Competitive: PV trial design relies on proving safety/efficacy thresholds against established injectable benchmarks; NTM program success hinges on overcoming the high refractoriness of the previous MAC trial population by shifting to M. abscessus.
• Timeline Uncertainty: Specific data readout dates depend on enrollment rates and statistical analysis outcomes.

Management Tone on the Future:

• High Confidence: Describes the Chagas program as "as sure of a bet as you can get" based on natural infection NHP models and similar EMA-approved drug (acoziboril).
• Optimistic yet Realistic: Expresses excitement and "bullish" sentiment regarding PV potential but acknowledges the need to validate safety/efficacy in human PV patients.
• De-risking: Highlights extensive safety database (105+ patients in NTM, 10 studies, hundreds of patient data points) and robust preclinical PK/PD modeling as unique risk mitigators.
• Aggressive Pace: Emphasizes a "quick pace" with multiple inflection points and milestone updates anticipated throughout 2027.

Miscellaneous:

• Mechanism of Action: Drug acts in late-stage erythropoiesis (globin synthesis) prior to reticulocyte formation; effect is predictable, monitorable, and reversible. Does not affect bone marrow progenitor cells.
• Competitive Moat: Claims unique boron chemistry with distinct IP freedom to operate compared to crowded PI3K and other kinase inhibitor spaces.
• Data Precedent: Cites Acoziboril (EMA approved for sleeping sickness) as a mechanistic proof-of-concept for their boron platform in trypanosome diseases.